Predictive Oncology (POAI) AI Stock Analysis

• Market Cap: $7.27M
• Dividend Yield: N/A
• Average Volume (3M): 173.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -38.79%
• EPS Growth: 58.27%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -3.30
• Shares Outstanding: 762,414
• 10 Day Avg. Volume: 72,596
• 30 Day Avg. Volume: 173,821
• PEG Ratio: 0.15
• Price to Book (P/B): -331.08
• Price to Sales (P/S): 41.31
• P/FCF Ratio: -6.11
• Enterprise Value/Market Cap: 1.26
• Enterprise Value/Revenue: 8.57
• Enterprise Value/Gross Profit: 26.26
• Enterprise Value/Ebitda: -1.16
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: $9.00 ▼(-2.60% Downside)

The overall stock score is heavily influenced by the company's poor financial performance and unfavorable technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low valuation score. The absence of earnings call data and corporate events means these factors did not impact the score.

Positive Factors

Innovative Business Model

The use of AI and machine learning in personalized medicine positions POAI at the forefront of innovative cancer treatment, potentially improving patient outcomes and reducing costs, which is a durable competitive advantage.

Revenue Diversification

Multiple revenue streams, including software sales and partnerships, provide financial resilience and growth potential, reducing dependency on a single income source and enhancing long-term stability.

Leadership Changes

New leadership with expertise in digital assets may drive strategic growth and innovation, aligning with emerging market trends and potentially enhancing the company's strategic direction and execution.

Negative Factors

Declining Revenue

A significant decline in revenue growth indicates challenges in market penetration or product adoption, which could impact long-term financial health and competitive positioning.

Negative Cash Flow

Persistent negative cash flow highlights liquidity issues, limiting the company's ability to invest in growth opportunities and manage financial obligations, posing a risk to sustainability.

Financial Instability

Negative equity and solvency concerns indicate a weak financial foundation, which can hinder the company's ability to raise capital and invest in future growth, threatening long-term viability.

Predictive Oncology Business Overview & Revenue Model

Company Description

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

How the Company Makes Money

Predictive Oncology generates revenue through multiple streams, including the sale of its predictive analytics software and services to healthcare providers and pharmaceutical companies. The company also engages in partnerships and collaborations with research institutions and biotech firms, which can lead to licensing agreements and joint ventures that further enhance its revenue potential. Additionally, POAI may receive funding through grants and investments aimed at supporting the development of its technological platform and expanding its product offerings. The combination of these revenue streams, along with the growing demand for personalized medicine solutions, contributes significantly to the company's financial performance.

Predictive Oncology Financial Statement Overview

Summary

Predictive Oncology faces significant financial challenges with declining revenues, negative profit margins, and deteriorating liquidity and solvency metrics. The company must address operational inefficiencies and stabilize its financial position.

Income Statement

The company shows a declining revenue trend with a negative revenue growth rate over the years. Gross profit margin has decreased from 64.7% in 2023 to 49.1% in 2024. The net profit margin is severely low due to net losses. EBIT and EBITDA margins are negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals financial instability with a negative stockholders' equity in 2024, indicating potential solvency issues. Debt-to-equity ratio is not applicable due to negative equity. The equity ratio is negative, reflecting a concerning capital structure.

Cash Flow

Operating cash flows remain negative, highlighting ongoing liquidity challenges. Free cash flow is also negative, but there is a slight improvement in free cash flow growth rate from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07M	1.62M	1.78M	1.51M	1.42M	1.25M
Gross Profit	349.12K	797.68K	1.02M	1.00M	933.66K	805.08K
EBITDA	-7.92M	-10.24M	-13.18M	-13.95M	-12.13M	-11.46M
Net Income	-9.78M	-12.20M	-13.98M	-25.74M	-19.66M	-25.88M
Balance Sheet
Total Assets	3.44M	4.97M	14.42M	25.73M	43.77M	13.06M
Cash, Cash Equivalents and Short-Term Investments	506.08K	734.67K	8.73M	22.07M	28.20M	678.33K
Total Debt	1.85M	2.13M	2.73M	180.32K	879.33K	5.87M
Total Liabilities	5.09M	5.18M	6.15M	3.97M	3.51M	10.42M
Stockholders Equity	-1.65M	-202.61K	8.27M	21.77M	40.27M	2.64M
Cash Flow
Free Cash Flow	-8.62M	-10.98M	-13.49M	-12.85M	-13.17M	-12.62M
Operating Cash Flow	-8.62M	-10.97M	-13.19M	-12.37M	-12.21M	-12.26M
Investing Cash Flow	689.00K	22.49K	-302.37K	-475.70K	-10.61M	-167.46K
Financing Cash Flow	3.92M	3.94M	148.90K	6.72M	50.34M	12.95M

Predictive Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POAI, the sentiment is Negative. The current price of 9.24 is below the 20-day moving average (MA) of 13.03, below the 50-day MA of 13.77, and below the 200-day MA of 15.91, indicating a bearish trend. The MACD of -1.24 indicates Positive momentum. The RSI at 32.23 is Neutral, neither overbought nor oversold. The STOCH value of 3.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POAI.

Predictive Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RVP	53 Neutral	$29.34M	―	-10.80%	―	-0.24%	50.45%
NXGL	53 Neutral	$27.70M	―	-66.08%	―	133.00%	29.69%
EKSO	52 Neutral	$12.64M	―	-96.44%	―	-19.32%	44.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HBIO	49 Neutral	$18.26M	―	-138.36%	―	-12.24%	-427.45%
POAI	38 Underperform	$7.27M	―	-708.73%	―	-38.79%	58.27%

Predictive Oncology Corporate Events

Predictive Oncology Schedules 2025 Annual Stockholder Meeting

Predictive Oncology has scheduled its 2025 annual meeting of stockholders for November 25, 2025, at DLA Piper LLP’s offices in Pittsburgh, Pennsylvania. The company has set October 24, 2025, as the record date for determining stockholders eligible to vote. Stockholders have until October 26, 2025, to submit proposals for consideration at the meeting. The company plans to distribute proxy materials around November 3, 2025, and may adjust these materials or the meeting date based on proposals received.

The most recent analyst rating on (POAI) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Closes $343.5M Private Placements

On October 8, 2025, Predictive Oncology announced the closing of two private placements totaling approximately $343.5 million, which occurred on October 7, 2025. The funds will support the company’s new digital asset treasury strategy focused on ATH, a utility token of the Aethir ecosystem. This initiative aligns with Predictive Oncology’s AI-driven drug discovery efforts and aims to enhance Aethir’s infrastructure for AI and machine learning globally. The strategic move is expected to create significant value for the company and its shareholders.

The most recent analyst rating on (POAI) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Enters Securities Purchase Agreements

Predictive Oncology Inc., a Delaware corporation, announced on September 29, 2025, that it entered into securities purchase agreements with accredited investors for private placements involving cash and cryptocurrency offerings. The company plans to issue common stock and pre-funded warrants, with the proceeds primarily used to establish a cryptocurrency treasury strategy focusing on digital assets like Aethir tokens. This strategic move aims to enhance the company’s financial positioning and operational capabilities, while also initiating a digital asset treasury strategy to manage and acquire digital assets. Additionally, changes in the board of directors were announced, with Nancy Chung-Welch resigning and Shawn Matthews being appointed, reflecting the company’s strategic alignment with its new digital asset focus.

The most recent analyst rating on (POAI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Announces $344.4M Private Placements

On September 29, 2025, Predictive Oncology Inc. announced two private placements totaling $344.4 million to support its new digital asset treasury strategy, focusing on Aethir (ATH) tokens. This strategic move aims to enhance the company’s operations by leveraging Aethir’s decentralized GPU network, potentially strengthening its market position and offering significant growth opportunities. The company plans to use the proceeds to acquire ATH tokens and fund general corporate purposes, with DNA Holdings Venture, Inc. as a strategic advisor. This initiative marks a significant step in Predictive Oncology’s expansion into digital assets, aligning with its core business of AI-driven drug discovery.

The most recent analyst rating on (POAI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Announces Reverse Stock Split Approval

On September 19, 2025, Predictive Oncology‘s stockholders approved a one-for-fifteen reverse stock split to comply with Nasdaq’s minimum bid price requirement. The reverse stock split, effective September 29, 2025, will reduce the number of outstanding shares and begin trading on a split-adjusted basis on September 30, 2025. This move aims to maintain the company’s listing on the Nasdaq Capital Market.

The most recent analyst rating on (POAI) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Approves New Equity Incentive Plan

On September 9, 2025, Predictive Oncology‘s Board of Directors approved the issuance of restricted stock units (RSUs) as part of their 2024 Equity Incentive Plan. This decision included granting 124,959 RSUs to CEO Raymond F. Vennare and 97,000 RSUs to Interim CFO Josh Blacher, with the RSUs set to vest on October 31, 2025, contingent on continued service.

The most recent analyst rating on (POAI) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Sells Shares to Accredited Investor

Predictive Oncology has issued and sold shares to an accredited investor under a Purchase Agreement. This transaction was conducted in reliance on exemptions from registration requirements under the Securities Act, indicating a strategic financial maneuver to potentially enhance the company’s capital structure.

The most recent analyst rating on (POAI) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Reports Significant Losses Amid Financial Challenges

Predictive Oncology Inc. is a company that leverages artificial intelligence and a proprietary biobank of over 150,000 tumor samples to enhance oncology drug discovery and development, aiming to improve cancer treatment outcomes. In its latest earnings report for the quarter ending June 30, 2025, Predictive Oncology highlighted a significant decrease in total assets from $4.97 million at the end of 2024 to $3.44 million, alongside a substantial net loss of $4.51 million for the first half of 2025. The company’s revenue for the same period was $112,992, a slight increase from the previous year, but operating expenses remained high, leading to continued losses. The company is facing financial challenges, including a stockholders’ deficit of $1.65 million and ongoing concerns about its ability to continue as a going concern without additional capital. Despite these challenges, Predictive Oncology is actively exploring various funding options to sustain operations and meet Nasdaq’s listing requirements, with a recent extension granted to demonstrate compliance by December 2025.

Predictive Oncology Granted Nasdaq Compliance Extension

Predictive Oncology Inc. faced potential delisting from The Nasdaq Capital Market due to non-compliance with the minimum stockholders’ equity and bid price requirements. After a hearing on July 17, 2025, Nasdaq granted the company an extension until December 8, 2025, to meet these requirements, though there is no assurance of compliance.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.